OCPD
MCID: OBS003
MIFTS: 44

Obsessive-Compulsive Personality Disorder (OCPD)

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Obsessive-Compulsive Personality Disorder

MalaCards integrated aliases for Obsessive-Compulsive Personality Disorder:

Name: Obsessive-Compulsive Personality Disorder 12 74 15
Obsessive-Compulsive Personality 54 71
Anankastic Personality Disorder 12 32
Compulsive Personality Disorder 43 71
Obsessional Personality Disorder 71
Obsessional Personality 12
Ocpd 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10932
ICD9CM 34 301.4
MeSH 43 D003193
NCIt 49 C92638
SNOMED-CT 67 1376001
ICD10 32 F60.5
UMLS 71 C0009595 C1704373 C3714689

Summaries for Obsessive-Compulsive Personality Disorder

Disease Ontology : 12 A personality disorder that is characterized by a pervasive pattern of preoccupation with orderliness, perfectionism, and mental and interpersonal control at the expense of flexibility, openness, and efficiency.

MalaCards based summary : Obsessive-Compulsive Personality Disorder, also known as obsessive-compulsive personality, is related to personality disorder and obsessive-compulsive disorder. An important gene associated with Obsessive-Compulsive Personality Disorder is DRD3 (Dopamine Receptor D3), and among its related pathways/superpathways are Bacterial invasion of epithelial cells and Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotype is digestive/alimentary.

Wikipedia : 74 Obsessive-compulsive personality disorder (OCPD) is a personality disorder characterized by excessive... more...

Related Diseases for Obsessive-Compulsive Personality Disorder

Diseases related to Obsessive-Compulsive Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Related Disease Score Top Affiliating Genes
1 personality disorder 31.7 SLC6A4 HTR2A DRD3
2 obsessive-compulsive disorder 30.9 SLITRK1 SLC6A4 HTR2A DRD3
3 avoidant personality disorder 30.8 WASF2 WASF1 SLC6A4 PIR DRD3 CLPS
4 eating disorder 30.7 SLC6A4 HTR2A DRD3
5 histrionic personality disorder 30.5 WASF2 WASF1 PIR
6 mental depression 30.4 WASF2 WASF1 SLC6A4 HTR2A
7 panic disorder 30.4 SLC6A4 HTR2A DRD3
8 separation anxiety disorder 30.4 WASF2 WASF1 SLC6A4
9 paraphilia disorder 30.4 PIR NT5M
10 social phobia 30.4 WASF2 WASF1 SLC6A4
11 intermittent explosive disorder 30.1 SLITRK1 SLC6A4 HTR2A
12 hypochondriasis 30.0 SLITRK1 SLC6A4 PIR HTR2A
13 neurotic disorder 29.9 SLC6A4 HTR2A
14 mood disorder 29.8 SLC6A4 HTR2A DRD3
15 tic disorder 29.8 SLITRK1 SLC6A4 HTR2A DRD3
16 gilles de la tourette syndrome 29.8 SLITRK1 SLC6A4 HTR2A DRD3
17 schizotypal personality disorder 29.8 WASF2 WASF1 PIR NT5M CLPS
18 disease of mental health 29.5 WASF2 WASF1 SLC6A4 HTR2A DRD3
19 severe combined immunodeficiency 10.6
20 major depressive disorder 10.6
21 depression 10.6
22 anxiety 10.5
23 borderline personality disorder 10.5
24 anorexia nervosa 10.5
25 supranuclear palsy, progressive, 1 10.4
26 barbiturate abuse 10.3 WASF2 WASF1
27 chronic tic disorder 10.3 SLITRK1 DRD3
28 attention deficit-hyperactivity disorder 10.3
29 hallucinogen dependence 10.3 WASF2 WASF1
30 cannabis abuse 10.3 WASF2 WASF1
31 kleptomania 10.2 SLITRK1 SLC6A4
32 tardive dyskinesia 10.2 HTR2A DRD3
33 oculogyric crisis 10.2 HTR2A DRD3
34 drug psychosis 10.2 HTR2A DRD3
35 drug-induced mental disorder 10.2 HTR2A DRD3
36 paranoid personality disorder 10.2 WASF2 WASF1 PIR
37 asperger syndrome 10.2
38 substance-induced psychosis 10.2 HTR2A DRD3
39 cyclothymic disorder 10.2 PIR HTR2A
40 ehlers-danlos syndrome, hypermobility type 10.1
41 multiple system atrophy 1 10.1
42 autism 10.1
43 bulimia nervosa 10.1
44 autism spectrum disorder 10.1
45 ehlers-danlos syndrome 10.1
46 hypermobility syndrome 10.1
47 generalized anxiety disorder 10.1
48 epilepsy 10.1
49 temporal lobe epilepsy 10.1
50 essential tremor 10.1

Comorbidity relations with Obsessive-Compulsive Personality Disorder via Phenotypic Disease Network (PDN):


Anxiety Dependent Personality Disorder
Dysthymic Disorder Generalized Anxiety Disorder
Hypothyroidism Major Depressive Disorder
Obsessive-Compulsive Disorder Schizophreniform Disorder

Graphical network of the top 20 diseases related to Obsessive-Compulsive Personality Disorder:



Diseases related to Obsessive-Compulsive Personality Disorder

Symptoms & Phenotypes for Obsessive-Compulsive Personality Disorder

MGI Mouse Phenotypes related to Obsessive-Compulsive Personality Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.1 CLPS DRD3 HTR2A SLC6A4 WASF1 WASF2

Drugs & Therapeutics for Obsessive-Compulsive Personality Disorder

Drugs for Obsessive-Compulsive Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4 64-17-5 702
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
4
Topiramate Approved Phase 4 97240-79-4 5284627
5
Norepinephrine Approved Phase 4 51-41-2 439260
6
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
7
Haloperidol Approved Phase 4 52-86-8 3559
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Citalopram Approved Phase 4 59729-33-8 2771
12
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
13
Cycloserine Approved Phase 4 68-41-7 401 6234
14
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
17
Sertraline Approved Phase 4 79617-96-2 68617
18
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
19
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
20
Maleic acid Experimental, Investigational Phase 4 110-17-8, 110-16-7 444972
21 Antipsychotic Agents Phase 4
22 Central Nervous System Depressants Phase 4
23 Tranquilizing Agents Phase 4
24 Quetiapine Fumarate Phase 4 111974-72-2
25 Antidepressive Agents, Tricyclic Phase 4
26 Dopamine Agents Phase 4
27 Dopamine Antagonists Phase 4
28 Autonomic Agents Phase 4
29 Hormones Phase 4
30 Calcium, Dietary Phase 4
31 calcium channel blockers Phase 4
32 Dopamine Uptake Inhibitors Phase 4
33 Central Nervous System Stimulants Phase 4
34 Antiparkinson Agents Phase 4
35 Muscarinic Antagonists Phase 4
36 Cholinergic Agents Phase 4
37 Parasympatholytics Phase 4
38 Cholinergic Antagonists Phase 4
39 Hypoglycemic Agents Phase 4
40 Duloxetine Hydrochloride Phase 4
41 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
42 Haloperidol decanoate Phase 4
43 Serotonin Receptor Agonists Phase 4
44 Acidophilus Phase 4
45 Antiprotozoal Agents Phase 4
46 Antiparasitic Agents Phase 4
47 Antimalarials Phase 4
48 Bifidobacterium Phase 4
49 Sulfalene Phase 4
50 Anti-Bacterial Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 361)
# Name Status NCT ID Phase Drugs
1 A Study of Topiramate Augmentation in Serotonin Reuptake Inhibitor (SRI) -Refractory Obsessive Compulsive Disorder Unknown status NCT00182520 Phase 4 Topiramate;placebo
2 Cost-Effectiveness of Adding Web-Based CBT to Luvox CR for OCD Unknown status NCT00743834 Phase 4 Luvox CR
3 Fear Conditioning, Extinction and Recall in Healthy Subjects and in Obsessive-compulsive Disorder Patients Pre and Post Treatment With Sertraline. Unknown status NCT03068429 Phase 4 Sertraline Hydrochloride
4 Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
5 Treatment With Escitalopram (Cipralex®) for Adolescents With Obsessive-Compulsive Disorder: Efficacy, Safety, and Changes in Executive Functions, Metacognition, and Regional Brain Activations. Unknown status NCT00708240 Phase 4 Escitalopram
6 Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder Completed NCT02194075 Phase 4 Fluvoxamine+Methylphenidate hydrochloride;Fluvoxamine+sugar pill
7 Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study Completed NCT00796497 Phase 4 ondansetron
8 Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder (Randomized, Double-blind, Multi-center Study) Completed NCT00723060 Phase 4 escitalopram
9 Ondansetron Augmentation in Treatment-resistant OCD Completed NCT01303536 Phase 4 Ondansetron
10 Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial. Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
11 Escitalopram for the Treatment of Obsessive Compulsive Disorder Completed NCT00116532 Phase 4 Escitalopram
12 Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder Completed NCT00211744 Phase 4 topiramate
13 Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
14 Reclaim® Deep Brain Stimulation Therapy for Obsessive-Compulsive Disorder: Post-Market Clinical Follow-up Study (OCD PMCF) Completed NCT01135745 Phase 4
15 Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
16 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
17 An Long Term Trial on Effectiveness and Safety of Atypical Antipsychotic Agents in Augmenting SSRI-Refractory Obsessive-Compulsive Disorder Completed NCT00854919 Phase 4 atypical antipsychotic drug
18 A Study of Pregabalin (Lyrica) Augmentation in Serotonin Reuptake Inhibitor-Refractory Obsessive Compulsive Disorder Completed NCT00994786 Phase 4 pregabalin;Placebo
19 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
20 Duloxetine for the Treatment of Obsessive Compulsive Disorder Completed NCT00464698 Phase 4 Duloxetine
21 SSRI-Induced Activation Syndrome in Pediatric Obsessive Compulsive Disorder Completed NCT00382291 Phase 4 Regular Titration;Placebo;Slow Titration
22 12 Week Prospective Double Blind Placebo Controlled Randomized Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
23 Group Cognitive Behavioral Therapy Versus Fluoxetine for Obsessive-Compulsive Disorder: a Randomized Open Trial for Any Patient. Completed NCT00680602 Phase 4 SSRI (fluoxetine, sertraline, paroxetine, citalopram)
24 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
25 Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD Recruiting NCT03993535 Phase 4 selective serotonin reuptake inhibitor
26 A 12-week Randomized Controlled Trial of Probiotic Treatment (Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) vs Placebo in Adult Obsessive Compulsive Disorder Recruiting NCT02334644 Phase 4
27 Controlled Trial of Deep Brain Stimulation for Obsessive-Compulsive Disorder Active, not recruiting NCT00640133 Phase 4
28 Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? A Randomized, Double-blind, Placebo-controlled National Study Active, not recruiting NCT02656342 Phase 4 D-Cycloserine;Placebo
29 Double-Blind, Randomized, Placebo-Controlled Trial of Naproxen Sodium for the Treatment of Obsessive Compulsive Symptoms in Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections (PANDAS) Not yet recruiting NCT04015596 Phase 4 Naproxen Sodium
30 Brief Intervention for OCD Fears Suspended NCT02790710 Phase 4 Propanolol;Placebo
31 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
32 SME3110 (Fluvoxamine Maleate) in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents (8 Through 18 Years of Age) -A Double-blind, Randomized, Placebo-controlled Study Terminated NCT00352768 Phase 4 Fluvoxamine maleate;Placebo
33 A Pilot Treatment Study of Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder Terminated NCT00592852 Phase 4 fluoxetine
34 Pharmacogenetics in Primary Care Psychotropics Unknown status NCT03232502 Phase 3
35 Safety and Effectiveness of Capsulotomy in Refractory Obsessive-Compulsive Disorder Unknown status NCT02375152 Phase 2, Phase 3
36 Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder: A Pilot Study Unknown status NCT02590445 Phase 2, Phase 3
37 Quetiapine Augmentation in Severe Obsessive Compulsive Disorder (OCD) - Pilot Study Completed NCT00254735 Phase 3 quetiapine fumarate;SSRI/Clomipramine
38 Family Based Treatment of Early Childhood OCD Completed NCT00055068 Phase 3
39 A Randomized, Double-Blind, Placebo-Controlled Medication Trial With D-Cycloserine for Individuals With OCD Currently Receiving Behavior Therapy Completed NCT00182000 Phase 3 seromycin
40 Comparison of the Efficacy of Subthalamic Nucleus, Caudate Nucleus and Nucleus Accumbens Electric Stimulation in Severe and Resistant Obsessive-compulsive Disorder. Completed NCT01807403 Phase 3
41 A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder Completed NCT01933919 Phase 3 Fluvoxamine maleate;Placebo
42 A Prospective Double Blind Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (dTMS) in Obsessive-Compulsive Subjects Completed NCT02229903 Phase 3
43 Research Unit on Pediatric Psychopharmacology Anxiety Treatment Study Completed NCT00000389 Phase 3 Fluvoxamine
44 2/3 Treatment of Anxiety in Autism Spectrum Disorder Completed NCT02028247 Phase 3
45 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder Completed NCT00187928 Phase 3 Topiramate
46 Differential Efficacy of Memantine for Obsessive-compulsive Disorder vs. Generalized Anxiety Disorder: an Open-label Trial Completed NCT00674219 Phase 3 Memantine
47 Family Based Treatment for Early Childhood OCD Completed NCT00533806 Phase 3
48 Behavior Therapy for Childhood OCD Completed NCT00000386 Phase 3
49 Treatment of Pediatric Obsessive-Compulsive Disorder Completed NCT00000384 Phase 3 Sertraline
50 Treatment of Pediatric OCD for SRI Partial Responders Completed NCT00074815 Phase 3 Serotonin reuptake inhibitors management

Search NIH Clinical Center for Obsessive-Compulsive Personality Disorder

Cochrane evidence based reviews: compulsive personality disorder

Genetic Tests for Obsessive-Compulsive Personality Disorder

Anatomical Context for Obsessive-Compulsive Personality Disorder

MalaCards organs/tissues related to Obsessive-Compulsive Personality Disorder:

40
Brain, Testes, Cortex, Subthalamic Nucleus, Skin, Caudate Nucleus, Thalamus

Publications for Obsessive-Compulsive Personality Disorder

Articles related to Obsessive-Compulsive Personality Disorder:

(show top 50) (show all 438)
# Title Authors PMID Year
1
Is problematic exercise really problematic? A dimensional approach. 61
30915933 2020
2
Comparing the interpersonal profiles of obsessive-compulsive personality disorder and avoidant personality disorder: Are there homogeneous profiles or interpersonal subtypes? 61
31944791 2020
3
Work Addiction, Obsessive-Compulsive Personality Disorder, Burn-Out, and Global Burden of Disease: Implications from the ICD-11. 61
31968540 2020
4
Radically Open Dialectical Behavior Therapy: Social Signaling, Transdiagnostic Utility and Current Evidence. 61
32021506 2020
5
Homicidal Ideation and Forensic Psychopathology: Evidence From the 2016 Nationwide Emergency Department Sample (NEDS). 61
31404481 2020
6
Altered spontaneous brain activity in obsessive-compulsive personality disorder. 61
31707312 2020
7
Personality disorders characterized by anxiety predict Alzheimer's disease in women: A case-control studies. 61
31833453 2019
8
Pineal gland volumes are changed in patients with obsessive-compulsive personality disorder. 61
31455564 2019
9
Obsessive-compulsive personality disorder features and response to behavioral therapy for insomnia among patients with hypnotic-dependent insomnia. 61
29869891 2019
10
Problematic use of the Internet is a unidimensional quasi-trait with impulsive and compulsive subtypes. 61
31703666 2019
11
Overlap of obsessive-compulsive personality disorder and autism spectrum disorder traits among OCD outpatients: an exploratory study. 61
31375037 2019
12
Obsessive compulsive personality traits: Understanding the chain of pathogenesis from health to disease. 61
31202047 2019
13
Obsessive-compulsive personality disorder symptoms as a risk factor for postpartum depressive symptoms. 61
30171361 2019
14
Editorial: Hoarding and Obsessive-Compulsive Disorder. 61
31108161 2019
15
Hippocampus and amygdalar volumes in patients with obsessive-compulsive personality disorder. 61
30962058 2019
16
An epidemiological survey of psychiatric disorders in Iran: Kermanshah. 61
31096141 2019
17
Volumetric MRI study of orbito-frontal cortex and thalamus in obsessive-compulsive personality disorder. 61
30962057 2019
18
Psychopathological and psychiatric evaluation of patients affected by lipodystrophy. 61
31144218 2019
19
A Psychometric Examination of the Pathological Obsessive Compulsive Personality Scale (POPS): Initial Study in an Undergraduate Sample. 61
29494778 2019
20
Crossed obsessive-compulsive personality disorder and impaired theory of mind in temporal lobe epilepsy. 61
30554354 2019
21
Association between cognitive impairments and obsessive-compulsive spectrum presentations following traumatic brain injury. 61
28043199 2019
22
The concurrent validity of a Web-based self-report assessment for personality disorders. 61
30592174 2019
23
Gender differences and similarities in aggression, suicidal behaviour, and psychiatric comorbidity in borderline personality disorder. 61
30353921 2019
24
[Attention-deficit/hyperactivity disorder (ADHD) in adult psychiatry: Data on 12-month prevalence, risk factors and comorbidity]. 61
29490380 2019
25
The role of personality disorders in obsessive-compulsive disorder. 61
30745684 2019
26
Obsessive-Compulsive Personality Symptoms Predict Poorer Response to Gamma Ventral Capsulotomy for Intractable OCD. 61
31998155 2019
27
Psychological impact of fibromyalgia: current perspectives. 61
30858740 2019
28
Personality disorder traits in young adults with subclinical obsessive-compulsive symptoms: Not just traits related to obsessive- compulsive personality. 61
31380698 2019
29
Obsessive, compulsive, and conscientious? The relationship between OCPD and personality traits. 61
29272027 2018
30
Prevalence of personality disorders in the general adult population in Western countries: systematic review and meta-analysis. 61
30261937 2018
31
Problematic overstudying: Studyholism or study addiction? 61
30541335 2018
32
The relationship between obsessive compulsive personality and obsessive compulsive disorder treatment outcomes: Predictive utility and clinically significant change - CORRIGENDUM. 61
29615137 2018
33
[The psychiatric comorbidity of anorexia nervosa: A comparative study in a population of French and Greek anorexic patients]. 61
29102367 2018
34
Recovery and Nonrecovery After Psychotherapy With Transference Interpretation: Two Case Studies. 61
30049221 2018
35
Examining the DSM-5 alternative model of personality disorders operationalization of obsessive-compulsive personality disorder in a mental health sample. 61
29927297 2018
36
Psychic euosmia and obsessive compulsive personality disorder. 61
30254981 2018
37
Gambling disorder and obsessive-compulsive personality disorder: A frequent but understudied comorbidity. 61
29936850 2018
38
ICD-11 and DSM-5 personality trait domains capture categorical personality disorders: Finding a common ground. 61
28835108 2018
39
Psychiatric (Axis I) and personality (Axis II) disorders and subjective psychiatric symptoms in chronic tinnitus. 61
29188734 2018
40
Psychological Factors Including Demographic Features, Mental Illnesses, and Personality Disorders as Predictors in Internet Addiction Disorder. 61
29997655 2018
41
Anxiety, Mood, and Personality Disorders in Patients with Benign Paroxysmal Positional Vertigo. 61
30042641 2018
42
Stability of the Pregnancy Obsessive-Compulsive Personality Disorder Symptoms Checklist. 61
29067550 2018
43
Associations Between Personality Disorder Characteristics, Psychological Symptoms, and Sexual Functioning in Young Women. 61
29276043 2018
44
Substance-use disorders, personality traits, and sex differences in institutionalized adolescents. 61
30067395 2018
45
Development and Examination of the Five-Factor Obsessive-Compulsive Inventory-Short Form. 61
27095820 2018
46
Continuity between DSM-5 Section II and Section III personality traits for obsessive-compulsive personality disorder. 61
29024130 2018
47
The role of cerebellar impairment in emotion processing: a case study. 61
30345063 2018
48
Suicidality in People With Obsessive-Compulsive Symptoms or Personality Traits. 61
30692943 2018
49
Examining the DSM-5 Section III Criteria for Obsessive-Compulsive Personality Disorder in a Community Sample. 61
28263093 2017
50
Interpersonal problems across levels of the psychopathology hierarchy. 61
28735709 2017

Variations for Obsessive-Compulsive Personality Disorder

Expression for Obsessive-Compulsive Personality Disorder

Search GEO for disease gene expression data for Obsessive-Compulsive Personality Disorder.

Pathways for Obsessive-Compulsive Personality Disorder

Pathways related to Obsessive-Compulsive Personality Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.66 WASF2 WASF1 SHC4
2 10.6 SLC6A4 HTR2A
3
Show member pathways
10.32 SLC6A4 DRD3

GO Terms for Obsessive-Compulsive Personality Disorder

Cellular components related to Obsessive-Compulsive Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.35 WASF2 WASF1 SLITRK1 SLC6A4 SHC4
2 SCAR complex GO:0031209 8.62 WASF2 WASF1

Biological processes related to Obsessive-Compulsive Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of dopamine secretion GO:0014059 9.32 HTR2A DRD3
2 digestion GO:0007586 9.26 PIR CLPS
3 Rac protein signal transduction GO:0016601 9.16 WASF2 WASF1
4 behavioral response to cocaine GO:0048148 8.96 HTR2A DRD3
5 negative regulation of synaptic transmission, glutamatergic GO:0051967 8.62 HTR2A DRD3

Molecular functions related to Obsessive-Compulsive Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase A binding GO:0051018 8.96 WASF2 WASF1
2 serotonin binding GO:0051378 8.62 SLC6A4 HTR2A

Sources for Obsessive-Compulsive Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....